Recommended dose modifications of capecitabine
| Toxicity CTCAE grades* | During the course of therapy | Dose adjustment for next treatment (% of starting dose) |
| Grade 1 | Maintain dose level | Maintain dose level |
| Grade 2 | ||
| 1st appearance | Interrupt until resolved to grade 0–1 | 100% |
| 2nd appearance | 75% | |
| 3rd appearance | 50% | |
| 4th appearance | Discontinue treatment permanently | – |
| Grade 3 | ||
| 1st appearance | Interrupt until resolved to grade 0–1 | 75% |
| 2nd appearance | 50% | |
| 3rd appearance | Discontinue treatment permanently | – |
| Grade 4 | ||
| 1st appearance | Discontinue treatment permanently or If physician decides continuation is in the patient’s best interest, interrupt until resolved to grade 0–1 | – 50% |
*Common Terminology Criteria for Adverse Events v.4.0, Japanese Clinical Oncology Group version.